ALK and non-small cell lung carcinoma: Crizotinib, a first-generation ALK and ROS1 inhibitor, has resulted in improved progression-free survival (PFS) relative to chemotherapy in the first- and second-line settings for ALK-rearranged (ALK+) NSCLC.